Data are available as Supporting Information file.

Introduction {#sec005}
============

Breast cancer is the second most common cancer worldwide. In 2012, the estimated number of new cases was 1.67 million (25% of all cancers). In Western Europe, there are 96 per 100,000 women with breast cancer \[[@pone.0203151.ref001]\].

According to the Spanish Society for Medical Oncology \[[@pone.0203151.ref002]\], the cancer incidence in Spain during the year 2015 was 247,771 cases (148,827 men and 98,944 women). Breast cancer has a greater incidence (27,747), a greater prevalence over 5 years, and a greater mortality rate (6,213 deaths during 2014) than other cancers \[[@pone.0203151.ref003]\]. The prevalence of breast cancer is increasing due to increased life expectancy and advanced diagnostic techniques for cancer \[[@pone.0203151.ref002], [@pone.0203151.ref003], [@pone.0203151.ref004]\].

The Spanish healthcare system is public with universal access. This system includes programs for the prevention, screening, and treatment of breast cancer \[[@pone.0203151.ref004]\]. Furthermore, there are associations that offer support to patients with cancer. For breast cancer, the most important association is the Spanish Federation of Breast Cancer (FECMA, by its initials in Spanish). FECMA has 27 centers in Spain.

Breast cancer treatment affects women's sexual function. These treatments, which include hormonal therapy, chemotherapy, and surgical treatment, can produce vaginal dryness, vasomotor symptoms, and loss of sexual satisfaction, loss of desire, and changes in self-image \[[@pone.0203151.ref005],[@pone.0203151.ref006],[@pone.0203151.ref007]\]. Studies addressing women's suffering from breast cancer have found that between 30 and 70% of patients present sexual dysfunction \[[@pone.0203151.ref005], [@pone.0203151.ref006], [@pone.0203151.ref007]\].

In Spain, no recent studies have addressed sexual dysfunction in women with breast cancer. Sexual function depends on several biological, psychological, and sociocultural factors. Here we investigate sexuality in women with breast cancer in Spain.

The aims of this study were: to determine if there are changes in the sexuality of women after breast cancer; to understand the sexual function of women with breast cancer in Spain; and to describe the relationship between socio-demographic and clinical variables with sexual dysfunction.

Methods {#sec006}
=======

Participants and design {#sec007}
-----------------------

This is a cross-sectional study carried out from June 2016 to January 2017. The population of the study consisted of 514 women with breast cancer who belonged to FECMA. Inclusion criteria: women with breast cancer, 18-years-old or older, and completed chemotherapy, radiotherapy or surgical intervention at least 3 months before the present study. Exclusion criteria: women with other cancers, metastases, and terminal conditions.

Sample size {#sec008}
-----------

The sample size was determined using Granmo software (version 7.12, Barcelona, Spain, 2012). This was calculated using a population estimate based on the study carried out by Panjari et al. (2011) \[[@pone.0203151.ref006]\], in which 70% of women with breast cancer suffered from sexual dysfunction, as well as the data offered by the Spanish Society for Medical Oncology \[[@pone.0203151.ref002]\] in which 27,747 women had breast cancer in Spain. Therefore, a sample of 355 women would be expected to be sufficient for an expected prevalence of 70%, a precision of 5%, a level of confidence of 95%, and a replacement rate of 10%.

Instruments {#sec009}
-----------

An online questionnaire was used to collect the different socio-demographic and clinical variables. This online questionnaire also included the *Questionnaire on Women\'s Sexual Function (WSF)* of Sánchez et al. (2004) \[[@pone.0203151.ref008]\]. This scale was created and validated to evaluate sexual function in Spanish women. It is a self-administered scale consisting of 14 items with a Likert scale with five options. Women were asked to answer in relation to the past 4 weeks. The first six questions refer to the different phases of the sexual response. Questions 7 and 8 assess the relational aspects of sexual activity. Questions 9 and 10 assess sexual satisfaction. The remaining questions address relevant aspects of sexual activity. The cut-points for the score range were: desire, excitation or arousal, penetration pain \[severe problem (1--3), moderate problem (4--7), without problem (8--15)\]; sexual satisfaction \[no satisfaction (1--2), moderate satisfaction (3--5), satisfaction (6--10)\]; lubrication, orgasm, and anticipatory anxiety \[severe problem (1), moderate problem (2), without problem (3--5)\]; sexual initiative \[abscense of initiative (1), moderate initiative (2), without problem (3--5)\]; and communication \[absence of sexual communication (1), moderate sexual communication (2), without problem (3--5)\]. This scale demonstrated an internal consistency of 0.895--0.897 and a reliability of 0.597--0.743 \[[@pone.0203151.ref008]\].

To determine whether the women had any sexual problem before cancer, the online survey had two questions: 1) "Before suffering cancer, have you had any sexual problem?"; 2) If your answer is "YES", could you specify what type of sexual problem you have had?"

Variable Sociodemographic and clinical {#sec010}
--------------------------------------

Age (quantitative), level of education (categorical), profession (categorical), civil status (categorical), type of surgical intervention (categorical), breast reconstruction (categorical), adjuvant treatment (categorical), sexual dysfunction before breast cancer (categorical), age of women at date of diagnosis (quantitative), and time elapsed after diagnosis (quantitative).

Variable of type of sexual dysfunction {#sec011}
--------------------------------------

Desire, excitation or arousal, lubrication, orgasm, penetration pain, anticipatory anxiety, sexual initiative, communication and sexual satisfaction (categorical variables).

Procedure {#sec012}
---------

Before the study, the FECMA directors were contacted and invited to participate in the study. They sent to their members an email with information about the study. The email included a direct access link to fulfill the online questionnaire available on Google Forms. When clicking on the link, the participants had to read the information sheet and provide informed consent to proceed with the questionnaire. The application respected the participant's anonymity.

This study conformed to the main principles of the Helsinki Declaration, the Universal Declaration of the UNESCO, and the Spanish Organic Law 15/1999, 13^th^ of December, on the Protection of Personal Data. The study was approved by FECMA. The participants were provided with an information sheet and gave informed consent. We respected the participants' anonymity at all times. The Ethical Committee authorized this study (CEITO N° Exp 138).

Data analysis {#sec013}
-------------

The statistics program IBM SPSS (version 22.0, licensed by the University of Castile La-Mancha, IBM Corp, Armonk, NY, USA) was used for statistical analysis. A descriptive analysis of the variables was performed by counting of recounts (n) and proportions (%) of the qualitative variables and by the average (m) and the standard deviation (SD) of quantitative variables.

Also, a proportional comparison of categorical variables through chi-square tests for contingency tables was provided. The variables, which were significates with sexual dysfunction in the contingency tables, were included in the regression model. A multiple logistic regression was performed to identify possible factors related to sexual dysfunction after suffering from breast cancer. We used the Wald statistic, such that the variables for which p ≥ 0.15 were eliminated one-by-one from the model. The odds ratios (OR) was calculated with their confidence intervals. All hypotheses were bilateral, and the level of confidence was 95% (p \< 0.05).

Results {#sec014}
=======

Five-hundred-twenty-seven women responded to the questionnaire, 13 of these completed the test incorrectly or incompletely. Finally, 514 women with breast cancer composed the size. The study participants were aged between 21- and 66-years-old (mean 46.34 ± 8.276 years), an average age at the date of diagnosis of 42.26 ± 8.563 years, and time suffering cancer of 4.05 ± 5.226 years. [Table 1](#pone.0203151.t001){ref-type="table"} shows the socio-demographic characteristics related to cancer treatment.

10.1371/journal.pone.0203151.t001

###### Socio-demographic and clinical variables of participants (n = 514).

![](pone.0203151.t001){#pone.0203151.t001g}

  -------------------------------------------- --------------- -------------------------
  Qualitative variables                        Frequency (N)   Percentage (%)
  Marital Status                                               
      Single without partner                   33              6.4
      Single with long-term partner            47              9.2
      Married women or living with a partner   346             67.3
      Divorced women with long-term partner    28              5.4
      Divorced women without partner           53              10.3
      Widowed without long-term partner        4               0.8
      Widowed with partner                     3               0.6
  Education                                                    
      Incomplete elementary                    3               0.6
      Elementary                               61              11.8
      High school                              225             43.8
      University                               225             43.8
  Occupation                                                   
      Unemployed                               106             20.6
      Employed                                 257             50
      Sick leave                               94              18.3
      Retired                                  57              11.1
  Surgical intervention                                        
      Lumpectomy                               195             37.9
      Mastectomy                               214             41.7
      Bilateral Mastectomy                     86              16.7
      Lymphadenectomy                          19              3.7
  Adjuvant treatment                                           
      Radiotherapy                             12              2.3
      Chemotherapy                             30              5.8
      Hormonal therapy                         25              4.9
      Radiotherapy and chemotherapy            63              12.2
      Radiotherapy and HT                      45              8.8
      Chemotherapy and HT                      64              12.5
      Radiotherapy, chemotherapy and HT        254             49.4
      No adjuvant treatment                    21              4.1
  Breast reconstruction                                        
      Yes                                      208             40.5
      No                                       185             36
      Not necessary                            121             23.5
  Quantitative Variables                       Mean (M)        Standard Deviation (SD)
  Age                                          46.3            8.3
  Age at diagnosis                             42.3            8.6
  Time elapsed following diagnosis             4.0             5.2
  -------------------------------------------- --------------- -------------------------

Regarding sexual activity ([Table 2](#pone.0203151.t002){ref-type="table"}), the majority of women did not present any sexual dysfunction before breast cancer diagnosis (66.9%). However, after having breast cancer (when the data were collected), 91.2% suffered from some type of sexual dysfunction. There are significant differences (p = 0.002) between the presence of sexual dysfunction before and after cancer.

10.1371/journal.pone.0203151.t002

###### Types of Sexual function of participants (n = 514).

![](pone.0203151.t002){#pone.0203151.t002g}

  Sexual Function                                    Frequency (N)   Percentage (%)
  -------------------------------------------------- --------------- ----------------
  Sexual Dysfunction before cancer                                   
      No                                             344             66.9
      Yes                                            170             33.1
  Sexual Dysfunction after cancer                                    
      No                                             45              8.8
      Yes                                            469             91.2
  Dysfunction Desire after cancer                                    
      Severe problem                                 43              8.4
      Moderate problem                               186             36.2
      Without problem                                285             55.4
  Dysfunction Excitation after cancer                                
      Severe problem                                 57              11.1
      Moderate problem                               177             34.4
      Without problem                                280             54.5
  Dysfunction due to Lubrication after cancer                        
      Severe problem                                 122             23.7
      Moderate problem                               138             26.9
      Without problem                                254             49.4
  Orgasm Dysfunction after cancer                                    
      Severe problem                                 121             23.5
      Moderate problem                               57              11.1
      Without problem                                336             65.4
  Dysfunction due to penetration pain after cancer                   
      Severe problem                                 50              9.7
      Moderate problem                               210             40.9
      Without problem                                254             49.4
  Dysfunction anticipatory Anxiety after cancer                      
      Severe problem                                 256             49.8
      Moderate problem                               86              16.7
      Without problem                                172             33.5
  Initiative sexual after cancer                                     
      Absence of initiative                          232             45.1
      Moderate Initiative                            96              18.7
      Without problem of initiative                  186             36.2
  Communication after cancer                                         
      Absence of sexual communication                132             25.7
      Moderate sexual Communication                  80              15.5
      Without problem of Sexual communication        302             58.8
  Level of satisfaction of sexual activity                           
      No satisfaction                                86              16.7
      Satisfaction moderate                          100             19.5
      Satisfactory                                   328             63.8
  Level of Sexual General Satisfaction                               
      Sexual general no satisfaction                 94              18.3
      Moderate Satisfaction                          79              15.4
      Satisfaction general                           341             66.3
      Motive no penetration                                          
      Pain                                           63              30.3
      Afraid to penetration                          6               2.9
      Lack of interest in vaginal penetration        71              34.1
      Without sexual partner                         54              26
      Incapacity of sexual partner                   14              6.7
  Sexual activity                                                    
      Yes                                            361             70.2
      No                                             153             29.8
  Frequency                                                          
      1--2 times a month                             312             60.7
      3--4 times a month                             110             21.4
      5--8 times a month                             69              13.4
      9--12 times a month                            23              4.5

[Table 2](#pone.0203151.t002){ref-type="table"} shows the types of sexual dysfunctions that women suffer after breast cancer. The most frequent dysfunctions were dysfunction due to penetration pain (50.6% of participants), dysfunction due to lubrication (50.6%), dysfunctional desire (44.6%), and dysfunctional excitation or arousal (44.6%). Regarding their sexual activity in the last 4 weeks, the majority usually had 1--2 instances of sexual activity per month (60.7%) and were satisfied with their sexual relations (66.3%). Finally, the most frequent reasons why these women did not want penetration during their sexual relations were a lack of interest in vaginal penetration (34.1%) and pain (30.3%).

The relationship between socio-demographic and clinical variables and the different types of sexual dysfunction in participants after cancer were studied ([Table 3](#pone.0203151.t003){ref-type="table"}). We found that women who received adjuvant treatments, radiotherapy, and hormonal therapy had a higher percentage of sexual dysfunction (p \< 0.001) compared to women who received other adjuvant treatments. Women who had a bilateral mastectomy (p = 0.009) had greater dysfunction than those who had a lumpectomy.

10.1371/journal.pone.0203151.t003

###### Socio- demographic variables of participants and relation with dysfunction sexual after cancer (n = 514).

![](pone.0203151.t003){#pone.0203151.t003g}

  ------------------------------------------------------- --------------------------------- ------------------ ---------
                                                          Sexual dysfunction after cancer   \                  
                                                                                            p                  

  Qualitative Variables                                   NO (n = 45)\                      YES (n = 469)\     
                                                          n (%)                             n (%)              

  Civil Status                                                                                                 0.138

      Single without partner                              3 (6.7)                           30 (6.4)           

      Single with long-term partner                       2 (4.4)                           45 (9.6)           

      Married women/ living with a partner                28 (62.2)                         318 (67.8)         

      Divorced women with partner                         6 (13.4)                          22 (4.7)           

      Divorced without partner                            5 (11.1)                          48 (10.2)          

      Widowed without partner                             0                                 4 (0.9)            

      Widowed with partner                                1 (2.2)                           2 (0.4)            

  Studios Level                                                                                                0.003

      Incomplete elementary                               0                                 3 (0.6)            

      Elementary                                          13 (28.8)                         48 (10.2)          

      High School                                         16 (35.6)                         209 (44.6)         

      University                                          16 (35.6)                         209 (44.6)         

  Occupation                                                                                                   0.414

      Unemployed                                          8 (17.8)                          98 (20.9)          

      Employed                                            23 (51.1)                         234 (49.9)         

      Sick leave                                          6 (13.3)                          88 (18.8)          

      Retired                                             8 (17.8)                          49 (10.4)          

  Surgical Intervention                                                                                        0.009

      Lumpectomy                                          26 (57.8)                         169 (36)           

      Mastectomy                                          17 (37.8)                         197 (42)           

      Bilateral Mastectomy                                2 (4.4)                           84 (17.9)          

      Lymphadenectomy                                     0                                 19 (4.1)           

  Adjuvant Treatment                                                                                           \<0.001

      Radiotherapy                                        5 (11.1)                          7 (1.5)            

      Chemotherapy                                        1 (2.2)                           29 (6.2)           

      Hormonal treatment                                  2 (4.4)                           23 (4.9)           

      Radiotherapy and chemotherapy                       3 (6.7)                           60 (12.8)          

      Radiotherapy and hormonal treat.                    9 (20)                            36 (7.7)           

      Chemotherapy and hormonal treat.                    5 (11.1)                          59 (12.6)          

      Radiotherapy, chemotherapy and hormonal treatment   17 (37.8)                         237 (50.5)         

      Nor adjuvant treatment                              3 (6.7)                           18 (3.8)           

  Reconstruction                                                                                               0.593

      Yes                                                 15 (33.3)                         193 (41.2)         

      No                                                  18 (40)                           167 (35.6)         

      Not necessary                                       12 (26.7)                         109 (23.2)         

  Quantitative Variables                                  NO\                               YES\               
                                                          M (SD)                            M (SD)             

  Age                                                     49 (±7.3)                         46.0 (±8.3)        0.006

  Age at diagnosis                                        45.9~~3~~ (±7.8)                  41.9~~4~~ (±8.5)   0.003

  Time elapsed following diagnosis                        3.6~~4~~ (±4.0)                   4.0~~9~~ (±5.3)    0.584
  ------------------------------------------------------- --------------------------------- ------------------ ---------

Using the significant variables, we created a multiple logistic regression model to understand whether the variables affected every type of sexual dysfunction (Tables [4](#pone.0203151.t004){ref-type="table"} and [5](#pone.0203151.t005){ref-type="table"}). In general, sexual dysfunction after cancer is associated with the age of women at the date of diagnosis (OR = 0.959; p = 0.029; 95%CI = 0.923--0.006) and surgical intervention. The probability of sexual dysfunction in women who have had a bilateral mastectomy is 4.684-times greater than those that had a lumpectomy (OR = 0.042; 95%CI = 1.056--20.784).

10.1371/journal.pone.0203151.t004

###### Logistic regression of sexual dysfunction after cancer (n = 514).

![](pone.0203151.t004){#pone.0203151.t004g}

                             OR (95% CI)             p
  -------------------------- ----------------------- -------
  Age at diagnosis           0.959 (0.923--0.996)    0.029
  Surgical Intervention                              
      Lumpectomy             Reference               
      Mastectomy             1.629 (0.847--3.133)    0.143
      Mastectomy bilateral   4.684 (1.056--20.784)   0.042
      Lymphadenectomy        22371 (0.007--0)        0.998

*Note*. Introduced variables: age at diagnosis, surgical intervention.

OR = Odds ratio; CI = confidence interval.

10.1371/journal.pone.0203151.t005

###### Logistical regression of type sexual dysfunction (n = 514).

![](pone.0203151.t005){#pone.0203151.t005g}

                                            Desire              Excitation   Lubrication         Orgasm   Penetration         Anxiety                                                                                   
  ----------------------------------------- ------------------- ------------ ------------------- -------- ------------------- --------- ------------------- --------- ------------------- --------- ------------------- -------
  *Age at diagnosis*                        1.04 (1.02--1.07)   \<0.001      1.04 (1.02--1.07)   0.001    1.06 (1.04--1.09)   \<0.001   1.05 (1.02--1.08)   \<0.001   1.03 (1.01--1.06)   0.006                         
  *Time elapsed f*. *diagnosis*                                                                           1.04 (0.99--1.08)   0.057                                   1.06 (1.02--1.10)   0.007     1.06 (1.02--1.11)   0.004
  *Surgical Intervention*                                                                                                                                                                                               
  Lumpectomy                                Reference                        Reference                    Reference                     Reference                                                                       
  Mastectomy                                1.59 (0.92--2.76)   0.1          1.25 (0.83--1.88)   0.29     1.08 (0.72--1.62)   0.724     1.62 (0.91--2.87)   0.105                                                       
  Bilateral Mastectomy                      2.88 (1.39--5.95)   0.004        2.02 (1.14--3.57)   0.015    2.30 (1.29--4.11)   0.005     2.93 (1.36--6.32)   0.006                                                       
  Lymphadenectomy                           2.02 (0.76--5.36)   0.159        2.37 (0.86--6.52)   0.094    2.26 (0.81--6.31)   0.12      1.25 (0.45--3.44)   0.671                                                       
  *Reconstruction*                                                                                                                                                                                                      
  Yes                                       Reference                                                                                   Reference                                                                       
  No                                        1.84 (1.13--2.98)   0.013                                                                   2.57 (1.54--4.29)   \<0.001                                                     
  Not necessary                             1.31 (0.65--2.63)   0.454                                                                   1.83 (0.87--3.86)   0.113                                                       
  *Civil Status*                                                                                                                                                                                                        
  Single/divorced/widowed without partner   0.78 (0.48--1.26)   0.308        0.99 (0.62--1.61)   0.98     0.78 (0.48--1.26)   0.313     1.79 (1.09--2.92)   0.021     2.55 (1.54--4.21)   \<0.001   1.05 (0.65--1.69)   0.84
  Single/divorced/widowed with partner      0.52 (0.29--0.9)    0.02         0.45 (0.25--0.80)   0.006    0.51 (0.30--0.88)   0.015     0.77 (0.42--1.40)   0.338     1.18 (0.70--1.97)   0.54      2.01 (1.19--3.39)   0.009
  Married women/living with a partner       Reference                        Reference                    Reference                     Reference                     Reference                     Reference           
  *Occupation*                                                                                                                                                                                                          
  Unemployed                                                                 0.53 (0.27--1.05)   0.07                                                                                               1.39 (0.71--2.74)   0.241
  Employed                                                                   0.48 (0.26--0.90)   0.021                                                                                              2.10 (1.14--3.86)   0.017
  Sick leave                                                                 0.78 (0.39--1.58)   0.495                                                                                              1.22 (0.60--2.48)   0.576
  Retired                                                                    Reference                                                                                                              Rererence           
  *Hormonal Treatment*                                                                                                                                                                                                  
  No                                                                                                      Reference                                                   Reference                     Reference           
  Yes                                                                                                     1.63 (1.06--2.51)   0.27                                    0.58 (0.38--0.88)             0.62 (0.41--0.95)   0.028

*Note*. Introduced variables = age at diagnosis, Time elapsed f diagnosis: time elapsed following diagnosis, Surgical intervention, reconstruction, civil status, occupation and hormonal treatment:

OR = Odds ratio; CI = confidence interval.

After analyzing the data related to the type of sexual dysfunction ([Table 5](#pone.0203151.t005){ref-type="table"}), we observed the following:

Sexual dysfunction related to desire is associated with the age of women at date of diagnosis, the type of surgical intervention (women who had a bilateral mastectomy had a 2.28-fold greater probability of dysfunction than those who had a lumpectomy), breast reconstruction (women who did not receive breast reconstruction had a 1.84-fold greater probability than those who did) and cohabitation (women with a partner but who are not living together had a 0.54-fold reduction in probability compared to women living with a partner).

Sexual dysfunction related to excitation is associated with the age of women at date of diagnosis, the type of surgical intervention (women who had a bilateral mastectomy had a 2.02-fold greater probability than those who had a lumpectomy), cohabitation (women with a partner but who are not living together have a 0.45-fold reduction in probability compared to women living with a partner) and profession (women who work have a 0.48-fold reduction in probability than those who are retired).

Sexual dysfunction related to lubrication is associated with the age of women at date of diagnosis, the time elapsed after cancer diagnosis, the type of surgical intervention (women who had a bilateral mastectomy had a 2.30-fold greater probability than those that had a lumpectomy), cohabitation (women with a partner but who are not living together have a 0.51-fold reduction in probability compared to women living with a partner), and hormonal therapy (women who had hormonal therapy have a 1.63-fold increased probability compared to those who have not been treated with hormones).

Sexual dysfunction related to orgasm is associated with the age of women at date of diagnosis, the type of surgical intervention (women who had a bilateral mastectomy have a 2.93-fold greater probability than those who had a lumpectomy), breast reconstruction (women who have not received a breast reconstruction have a 2.57-fold greater probability than those who had), and cohabitation (women with a partner but who are not living together have a 1.79-fold increased probability compared to women living with a partner).

Sexual dysfunction related to penetration is associated with the age of women at date of diagnosis, the time elapsed after cancer diagnosis, cohabitation (women with a partner but who are not living together have a 2.55-fold reduction in probability compared to women living with a partner), and hormonal therapy (women who have had hormonal therapy have a 0.58-fold increased probability compared to those who have not been treated with hormones).

Anticipatory sexual anxiety is associated with the time elapsed after cancer diagnosis, cohabitation (women with partner but who are not living together have a 2.01-fold reduction in probability compared to women living with a partner), occupation (women who work have a 2.10-fold increase in probability than those who have retired), and hormonal therapy (women who have had hormonal therapy have a 0.62-fold reduction in probability compared to those who have not been treated with hormones).

Discussion {#sec015}
==========

According to other studies \[[@pone.0203151.ref006], [@pone.0203151.ref009], [@pone.0203151.ref010], [@pone.0203151.ref011], [@pone.0203151.ref012]\], women who have suffered from breast cancer report that their sexuality is changed. However, before cancer, 66.9% did not have any type of sexual difficulty. After breast cancer, 91.2% reported that they had some type of sexual difficulty. This incidence is higher than other studies, where it was found to vary from 40 to 80% \[[@pone.0203151.ref005], [@pone.0203151.ref006], [@pone.0203151.ref009], [@pone.0203151.ref013], [@pone.0203151.ref014]\]. This could be because women participating in this study were young; the average age was 46.34-years-old.

After cancer, the majority of women in this study (70.2%) confirmed that they continued to have sexual activity, with is consistent with the literature \[[@pone.0203151.ref014], [@pone.0203151.ref015], [@pone.0203151.ref016]\]. Although the frequency of sexual relations is lower after cancer, 60.7% reported that they have sexual relationships 1--2 times per month \[[@pone.0203151.ref005], [@pone.0203151.ref009], [@pone.0203151.ref012], [@pone.0203151.ref016]\].

The main sexuality problems are decreased sexual desire \[[@pone.0203151.ref006], [@pone.0203151.ref009],[@pone.0203151.ref011], [@pone.0203151.ref014], [@pone.0203151.ref017], [@pone.0203151.ref018], [@pone.0203151.ref019]\], lubrication \[[@pone.0203151.ref005], [@pone.0203151.ref006], [@pone.0203151.ref011], [@pone.0203151.ref018], [@pone.0203151.ref019]\], excitation or arousal \[[@pone.0203151.ref010], [@pone.0203151.ref011], [@pone.0203151.ref016], [@pone.0203151.ref018], [@pone.0203151.ref019], [@pone.0203151.ref020]\], and penetration pain \[[@pone.0203151.ref012], [@pone.0203151.ref019]\].

Regarding the treatment and presence of sexual dysfunction, participants who had received chemotherapy presented more sexual problems that those who were not treated with chemotherapy \[[@pone.0203151.ref009], [@pone.0203151.ref021], [@pone.0203151.ref022]\]. However, these results are different from other studies reporting that chemotherapy is not associated with sexual dysfunction \[[@pone.0203151.ref006], [@pone.0203151.ref014]\]. Our data agree with Malinovszky et al. \[[@pone.0203151.ref023]\], in which premenopausal women with breast cancer who had received chemotherapy declared that they suffered decreased sexual pleasure and increased discomfort \[[@pone.0203151.ref023]\].

In our study, the majority of women were treated with hormonal therapy (75.7%) (e.g., aromatase inhibitors or tamoxifen), which led to early menopause. As found in other studies, the use of these drugs is related to reduced vaginal lubrication, decreased sexual satisfaction, and loss of sexual desire \[[@pone.0203151.ref006], [@pone.0203151.ref013], [@pone.0203151.ref017], [@pone.0203151.ref018], [@pone.0203151.ref024], [@pone.0203151.ref025]\].

The type of surgical intervention is associated with the presence of sexual dysfunction. Women with lumpectomy present fewer dysfunctions that those who have a unilateral mastectomy or a bilateral mastectomy \[[@pone.0203151.ref006], [@pone.0203151.ref009], [@pone.0203151.ref026], [@pone.0203151.ref027]\]. Women without breast reconstruction have the greatest probability of sexual dysfunction \[[@pone.0203151.ref028]\].

Women who were old at the age of diagnosis reported that they had more sexual problems \[[@pone.0203151.ref029], [@pone.0203151.ref030]\]. However, the young women after treatment had less sexual dysfunction, because their ovaries can continue to work properly. On the other hand, in premenopausal and perimenopausal women, ovarian function is usually affected for a long period following chemotherapy and hormonal therapy \[[@pone.0203151.ref031]\].

Civil status is associated with the presence of several sexual dysfunctions. Women without a partner do not have problems related to orgasm and penetration. Another finding is that women who have a steady partner but do not cohabitate have fewer problems related to desire, excitement, and lubrication compared to married women or couples living together. Although we found no study similar to ours, Morais et al. \[[@pone.0203151.ref014]\] reported that women without a steady partner have better sexual satisfaction due to multiple partners.

The study has some limitations. First, a cross-sectional design was used, so it is not possible to establish causal relationships. Second, a convenience sample was used. Finally, the online questionnaire prevents women from asking about any doubts they might have, and the analyzed data are self-reported information. However, on the other hand, the online questionnaire has the strength that the women can provide detailed answers about their sexuality more freely and without shame, which is not always possible in a face-to-face interview.

Furthermore, although the sample was recruited for convenience, it has a large size (more than 500 women). Also, we believe that the women can adequately respond to questions addressing their clinical situation. This is because, in Spain, the Health System is public and the physicians are obligated to give to their patients (in this case, women with breast cancer) a report that includes specific information about their type of cancer, type of surgery, and type of treatment.

Our findings highlight the impact of breast cancer treatments on female sexuality and the impact in women with breast cancer.

Based on our findings, it is necessary that health professionals recognize which variables influence sexual function in women with breast cancer. A multidisciplinary team should plan interventions to facilitate sexual adjustment.

Furthermore, women with breast cancer are capable of choosing whether to be sexually active or not. It is the duty of health professionals to guarantee that women with breast cancer and their partners receive accurate information about sexuality, treatment, and emotional support \[[@pone.0203151.ref032]\].

Conclusion {#sec016}
==========

Sexual function changes after breast cancer. Ninety percent of cases suffer from some type of sexual dysfunction. The most frequent problems are dysfunction due to penetration pain, lubrication, desire, and excitation. The type of surgical intervention, hormonal therapy, age, and civil status are associated with the presence of sexual dysfunction.
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